Immunic (IMUX) Other Accumulated Expenses (2013 - 2026)

Immunic (IMUX) has 14 years of Other Accumulated Expenses data on file, last reported at $4.9 million in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses rose 280.8% year-over-year to $4.9 million; the trailing twelve-month figure through Mar 2026 stood at $4.9 million (up 280.8% YoY), and the FY2025 full-year result was $1.8 million, up 29.59% from the prior year.
• Other Accumulated Expenses climbed to $4.9 million in Q1 2026, from $1.8 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $4.9 million in Q1 2026 to a low of $544000.0 in Q2 2022.
• A 5-year average of $1.3 million and a median of $966000.0 in 2023 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses plunged 86.83% in 2022 and soared 280.8% in 2026, its largest moves.
• Tracing IMUX's Other Accumulated Expenses over 5 years: stood at $810000.0 in 2022, then climbed by 19.26% to $966000.0 in 2023, then surged by 46.58% to $1.4 million in 2024, then climbed by 29.59% to $1.8 million in 2025, then soared by 168.12% to $4.9 million in 2026.
• Business Quant data shows IMUX's Other Accumulated Expenses at $4.9 million in Q1 2026, $1.8 million in Q4 2025, and $2.7 million in Q3 2025.